MAPK3 and melanoma: To assess the on-target efficacy of vemurafenib to inhibit BRAFV600E activity in zebrafish melanoma, we performed immunofluorescence staining of melanoma sections to assess the MAPK pathway activity using phospho-Erk1/2, a downstream target of activated BRAF signalling.